Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment
- PMID: 17287448
- DOI: 10.1212/01.wnl.0000258542.58725.4c
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment
Abstract
Objective: To investigate the neurocognitive measures that best predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD).
Methods: We evaluated 539 participants with aMCI from the Alzheimer's Disease Cooperative Study clinical drug trial of donepezil, vitamin E, or placebo. During the study period of 36 months, 212 aMCI participants progressed to AD. Using progression from aMCI to AD within 36 months as the dependent variable, a generalized linear model was fit to the data using the least absolute shrinkage and selection operator. Independent variables included in this analysis were age, sex, education, APOE-e4 (APOE4) status, family history of dementia, Mini-Mental State Examination score, Digits Backwards (Wechsler Memory Scale), Maze Time and Errors, Number Cancellation, Delayed Recall of Alzheimer's Disease Assessment Scale Word List, New York University Paragraph Recall Test (Immediate and Delayed), Boston Naming Test, Category Fluency, Clock Drawing Test, and the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog).
Results: The model that best predicted progression from aMCI to AD over 36 months included APOE4 status, the Symbol Digit Modalities Test, Delayed 10-Word List Recall, New York University Paragraph Recall Test (Delayed), and the ADAS-cog total score. When APOE4 was removed from the analysis the resulting model had a similar estimated predictive accuracy as the full model. As determined by cross-validation, the estimated predictive accuracy of the final model was 80%.
Conclusion: Progression from amnestic mild cognitive impairment to Alzheimer disease in this cohort was best determined by combining four common, easily administered, cognitive measures.
Similar articles
-
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65. Neurology. 2008. PMID: 18195264 Clinical Trial.
-
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825439 Free PMC article. Clinical Trial.
-
Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.Alzheimers Dement. 2010 Sep;6(5):412-9. doi: 10.1016/j.jalz.2009.12.003. Alzheimers Dement. 2010. PMID: 20813342 Free PMC article.
-
[Mild Cognitive Impairment: potential therapeutics].Rev Neurol (Paris). 2002;158(10 Suppl):S35-40. Rev Neurol (Paris). 2002. PMID: 12529584 Review. French.
-
Predicting cognitive decline in Alzheimer's disease: an integrated analysis.Alzheimers Dement. 2010 Nov;6(6):431-9. doi: 10.1016/j.jalz.2010.04.003. Alzheimers Dement. 2010. PMID: 21044773 Review.
Cited by
-
Treatment of Mild Cognitive Impairment.Curr Treat Options Neurol. 2015 Sep;17(9):372. doi: 10.1007/s11940-015-0372-3. Curr Treat Options Neurol. 2015. PMID: 26208489
-
The development and evaluation of triage algorithms for early discovery of adverse drug interactions.Drug Saf. 2013 May;36(5):371-88. doi: 10.1007/s40264-013-0053-7. Drug Saf. 2013. PMID: 23640657
-
Diagnostic accuracy of the RBANS in mild cognitive impairment: limitations on assessing milder impairments.Arch Clin Neuropsychol. 2010 Aug;25(5):429-41. doi: 10.1093/arclin/acq045. Epub 2010 Jun 21. Arch Clin Neuropsychol. 2010. PMID: 20570820 Free PMC article.
-
Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study.J Natl Med Assoc. 2008 Nov;100(11):1350-8. doi: 10.1016/s0027-9684(15)31515-7. J Natl Med Assoc. 2008. PMID: 19024233 Free PMC article.
-
Neuropsychological predictors of conversion from mild cognitive impairment to dementia at different timepoints.Brain Behav. 2023 Sep;13(9):e3098. doi: 10.1002/brb3.3098. Epub 2023 Aug 7. Brain Behav. 2023. PMID: 37550896 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous